Ouroboros Medical, Inc., an early stage medical device company focused on developing minimally invasive spine products for degenerated disc disease, has received approval to market Ouroboros’s spinal fusion product in Europe. Additionally, Ouroboros Medical recently accepted an award in November at the 2009 Spine Technology Summit Awards, for being a novel minimally invasive lumbar spine fusion device…

See original here: 
Ouroboros Medical Inc. Establishes European Approval And Awarded 2009 Spine Technology Summit Award

Related posts:

1. European Midwifery Regulators Strengthen Co-operation At A Second SummitWorking together to protect the wellbeing of women and babies was the aim of a summit of European midwifery regulators held in Brussels last week (20 November 2009). Hosted by...
2. Hospital For Special Surgery Establishes A Comprehensive Spine Care InstituteHospital for Special Surgery announced the establishment of one of the most comprehensive centers of excellence in the country for the treatment of all nonoperative and operative spine disorders. The...
3. Assembly Of First Nations And Health Canada To Co-host A Virtual Summit On H1N1 Preparedness November 10th, 2009On November 10, 2009 at 12:00 noon EST Health Minister Leona Aglukkaq and National Chief of the Assembly of First Nations (AFN) Shawn Atleo will co-host a Virtual Summit on...
4. European Medical Advisory Committee Does Not Recommend Approval Of Avastin For Deadly Form Of Brain CancerRoche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have...
5. Scientific Presentations At 2009 ASTRO Meeting Highlight RapidArc(R) Radiotherapy Technology From Varian Medical SystemsClinicians using RapidArc® radiotherapy technology for fast, precise, non-invasive cancer treatments have found that they are able to substantially reduce scatter dose to surrounding healthy tissues, according to several presentations...
6. Basilea’s Toctino(R) Recommended For Approval In 15 Additional European CountriesBasilea Pharmaceutica Ltd. (SWISS: BSLN) announces that Toctino® (alitretinoin) was recommended for regulatory approval under the Repeat-use Procedure in 13 additional European Union (EU) Member States as well as in...
7. Over 20 Senior Level Speakers Will Gather At MDDexec’s European Sales And Marketing Summit, 17-18 March 2010, LondonRepresentatives from leading corporates such as Boston Scientific, DePuy, Hospira and Philips Healthcare are set to gather in March to share best practice alongside more than fifteen fellow executives for...
8. AAN Awards Rochester Neurologist With Education AwardThe American Academy of Neurology has awarded Ralph F. Józefowicz, MD, FAAN, of the University of Rochester School of Medicine and Dentistry in New York, the 2010 A.B. Baker Award...
9. MagForce Nanotechnologies AG Applies For European Regulatory Approval Of Its Nano-Cancer(R) TherapyMagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products....
10. Gore Receives European CE Mark Approval For Next Generation Conformable GORE TAG(R) Thoracic EndoprosthesisW.L. Gore & Associates (Gore) announced that it has received European CE Mark approval for the next generation GORE TAG® Thoracic Endoprosthesis. ...
11. ASH Announces 2009 Merit Award WinnersThe American Society of Hematology (ASH) is pleased to recognize the following abstract presenters with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident...
12. Small Things Considered Wins Big At PRNews’ 2009 Nonprofit AwardsSmall Things Considered, a microbiology blog published by the American Society for Microbiology (ASM), has been honored with a non-profit public relations award from PR News for best blog. The...
13. The Medicines Company Receives European Approval For Angiox(R) (Bivalirudin) For Use In Heart Attack Patients Undergoing Emergency Heart ProceduresThe Medicines Company (NASDAQ: MDCO) announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation...
14. University Of Texas Southwestern Medical Center Researcher Wins Avanti Award In LipidsThe 2010 Avanti Award in Lipids, which recognizes outstanding research contributions in the area of lipid research, has been awarded to David W. Russell, the Eugene McDermott distinguished chair of...
15. Novartis Receives Approval In The European Union For Onbrez® Breezhaler®, A New Once-daily Bronchodilator For Patients With COPDNovartis announced that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of...